肺癌藥物市場按治療層級、癌症類型、分子類型、給藥途徑、最終用戶和分銷管道分類－2025-2032 年全球預測

預計到 2032 年肺癌藥物市場規模將成長至 550.7 億美元，複合年成長率為 9.32%。

權威介紹分子科學、免疫腫瘤學的進步以及治療方法的變化如何改變肺癌治療決策和重點

分子科學、不斷發展的臨床範例和不斷變化的醫療服務模式正在徹底重塑肺癌治療模式。近年來，肺癌治療已從「一刀切」的細胞毒性療法轉向利用腫瘤生物學、免疫調節和精準標靶的治療方法。在此背景下，臨床醫生、支付方和研發方在先進的診斷技術和基於生物標記的入組方案的驅動下，面臨著關於定序、組合方案和患者選擇的新選擇。

因此，相關人員必須協調加速的科學進步與獲取途徑、生產複雜性和監管導向等方面的實際限制。單株抗體與小分子藥物之間的相互作用、系統性免疫療法與標靶抑制劑的興起，以及口服藥物在門診環境中日益重要的作用，正在重塑治療流程。隨著醫療保健系統的不斷調整，人們越來越重視多學科協作、真實世界證據的生成以及可擴展的給藥途徑，以在確保安全性的同時最佳化療效。

本介紹為深入了解變革性轉變、政策和關稅影響、基於細分的見解、區域動態、競爭行為和可行建議奠定了基礎，以便為整個肺癌治療生態系統的策略規劃提供資訊。

免疫腫瘤學、精準標靶、門診趨勢和不斷發展的診斷技術如何改變腫瘤學臨床路徑和商業策略

科學突破正在推動肺癌診斷、治療和管理方式的變革。針對 CTLA-4、PD-1 和 PD-L1 路徑的免疫治療藥物已從小眾適應症轉變為許多患者的基礎治療，而針對 ALK、EGFR 和 ROS1 變異的標靶治療通常成為針對特定分子群體的第一線治療策略。同時，免疫調節與化療和分子標靶藥物的聯合治療正在重新定義療效預期和毒性管理。

這些治療方法進展與營運模式的轉變相輔相成。越來越多的治療在院外進行，包括為門診或居家患者量身定做的口服和腸外治療方案，數位健康和​​遠端監控工具可支援依從性和不利事件監測。次世代定序和液態切片技術正在擴展診斷能力，實現更早、更準確的患者分層，從而提升了整合策略的重要性。法律規範正在不斷調整，以加快核准，要求提供真實世界證據，並加強對安全訊號的審查，這為開發商和醫療保健提供者帶來了機遇，也帶來了複雜性。

總的來說，這些發展要求相關人員重新思考臨床路徑、供應鏈彈性和相關人員參與模式，以利用治療潛力，同時保護病患的治療機會和系統永續性。

近期美國貿易關稅對腫瘤學跨境供應鏈、臨床物流、定價壓力和策略製造選擇的累積影響

美國將於2025年引入累積關稅，這對全球供應鏈、籌資策略以及肺癌治療藥物的定價產生了連鎖反應。依賴跨境供應原料藥、生物製藥成分和成品的製造商正面臨不斷上升的到岸成本，需要重新協商供應商合約、進行區域採購並重新分配產能。因此，採購團隊和委託製造製造商不得不重新評估供應商多元化和庫存策略，以減輕影響。

關稅也影響臨床試驗的開展，因為臨床試驗中心和申辦者正在重新評估臨床實驗藥物分銷的物流，尤其是依賴低溫運輸完整性的腸外生技藥品。付款方和醫院系統面臨利潤壓力，成本效益和利用管理機制的審查也日益嚴格。此外，關稅促使一些機構投資國內生產能力，並尋求策略夥伴關係關係，以確保供應的連續性。

關稅加劇了摩擦，但也催化了適應策略，這些策略強調區域韌性、監管協調以及以可證明的患者獲益為中心的商業模式。重視供應鏈透明度、靈活生產和協作承包的相關人員更有可能成功應對不斷變化的貿易格局。

基於細分的關鍵見解，將治療層級、癌症類型、分子類別、給藥途徑和通路與商業和臨床策略聯繫起來

細分市場揭示了不同的臨床需求和商業性途徑，需要針對開發商和供應商制定量身定做的方案。根據治療層級，這些類別包括化療和聯合治療、CTLA-4、PD-1 和 PD-L1 抑制劑的免疫療法，以及包括 ALK、EGFR 和 ROS1 抑制劑在內的標靶治療。每類藥物都有各自的療效特徵、安全性和監測要求，這些都會影響處方和用藥模式。根據癌症類型，非小細胞肺癌和小細胞肺癌的治療模式也有所不同，分子譜和治療反應也存在顯著差異，導致診斷和治療途徑也有所不同。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• KRAS G12C 抑制劑的快速推出正在重塑非小細胞肺癌的二線治療策略
• 將微量殘存疾病監測與液態生物檢體結合，指導非小細胞肺癌的輔助性治療決策
• 針對 PD-L1 和 LAG-3 的雙特異性抗體在早期肺癌臨床試驗中擴展
• 個人化新抗原疫苗的出現增強了肺癌免疫治療的療效
• EGFR 抑制劑和 VEGF 拮抗劑在 EGFR 突變 NSCLC 的加速聯合治療

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：按治療層級的肺癌藥物市場

• 化療
• 聯合治療
• 免疫療法
  • Ctla-4抑制劑
  • Pd-1抑制劑
  • Pd-L1抑制劑
• 標靶治療
  • 鹼性抑制劑
  • EgfR抑制劑
  • Ros1抑制劑

第9章肺癌治療藥物市場（依癌症類型）

• 非小細胞肺癌
• 小細胞肺癌

第 10 章肺癌藥物市場（依分子類型）

• 單株抗體
• 小分子藥物

第11章肺癌藥物市場依給藥途徑

• 口服
• 腸外

第12章肺癌藥物市場（依最終用戶）

• 居家照護環境
• 醫院
• 專科診所

第13章肺癌藥物市場（按分銷管道）

• 醫院藥房
• 網路藥局
• 零售藥局

第14章肺癌藥物市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第15章肺癌藥物市場（依類別）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第16章 肺癌藥物市場（依國家）

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第17章競爭格局

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Novartis International AG
  • Boehringer Ingelheim International GmbH
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • AbbVie Inc.
  • Amgen Inc.

The Lung Cancer Drugs Market is projected to grow by USD 55.07 billion at a CAGR of 9.32% by 2032.

An authoritative introduction to how molecular science, immuno-oncology advances and care delivery changes are reshaping lung cancer treatment decisions and priorities

The lung cancer therapeutic landscape is undergoing a dramatic redefinition driven by molecular science, evolving clinical paradigms, and shifting care delivery models. Recent years have seen a transition from one-size-fits-all cytotoxic approaches toward therapies that exploit tumor biology, immune modulation, and precision targeting. Against this backdrop, clinicians, payers, and developers are confronting new choices about sequencing, combination regimens, and patient selection that hinge on diagnostic sophistication and biomarker-driven enrollment.

Consequently, stakeholders must reconcile accelerating scientific progress with practical constraints in access, manufacturing complexity, and regulatory navigation. The interplay between monoclonal antibodies and small molecule drugs, the ascendancy of systemic immunotherapies alongside targeted inhibitors, and the growing role of oral agents in outpatient care are reshaping treatment algorithms. As healthcare systems adapt, the emphasis shifts toward multidisciplinary coordination, real-world evidence generation, and scalable delivery pathways that preserve safety while optimizing outcomes.

This introduction sets the stage for a deeper examination of transformative shifts, policy and tariff implications, segmentation-driven insights, regional dynamics, competitive behaviors, and pragmatic recommendations that collectively inform strategic planning across the lung cancer therapeutics ecosystem.

How immuno-oncology, precision targeting, outpatient delivery trends and evolving diagnostics are collectively transforming clinical pathways and commercial strategies in oncology

Scientific breakthroughs have precipitated transformative shifts in how lung cancer is diagnosed, treated, and managed across care settings. Immunotherapy agents that target CTLA-4, PD-1, and PD-L1 pathways have moved from niche indications to foundational therapies for many patients, and targeted therapies against ALK, EGFR, and ROS1 alterations routinely define first-line strategies for molecularly selected populations. Simultaneously, combination therapy paradigms that pair immunomodulators with chemotherapy or targeted agents are redefining response expectations and toxicity management.

These therapeutic advances coincide with operational shifts: more care is delivered outside the inpatient setting via oral and parenteral regimens tailored to outpatient and homecare administration, while digital health and remote monitoring tools support adherence and adverse event surveillance. Diagnostic capabilities have expanded with next-generation sequencing and liquid biopsy techniques enabling earlier and more precise patient stratification, which in turn elevates the importance of integrated diagnostic-commercial strategies. Regulatory frameworks are adapting to accelerated approvals, real-world evidence requirements, and greater scrutiny of safety signals, creating both opportunities and complexities for developers and providers.

Taken together, these developments demand that stakeholders rethink clinical pathways, supply chain resilience, and stakeholder engagement models to capitalize on therapeutic potential while safeguarding patient access and system sustainability.

The cumulative impact of recent United States trade tariffs on cross-border supply chains, clinical logistics, pricing pressure and strategic manufacturing choices in oncology

The introduction of cumulative tariffs implemented in the United States in 2025 has created a ripple effect across global supply chains, procurement strategies, and pricing arrangements for lung cancer therapeutics. Manufacturers reliant on cross-border supply of active pharmaceutical ingredients, biologic components, or finished goods have faced elevated landed costs that necessitate renegotiation of supplier contracts, regionalized sourcing, or reallocation of production capacity. Consequently, procurement teams and contract manufacturers have had to revisit supplier diversification and inventory strategies to mitigate disruptions.

Clinical trial conduct has also been influenced as sites and sponsors reassess logistics for investigational product distribution, particularly for parenteral biologics that depend on cold-chain integrity. Payers and hospital systems, grappling with margin pressures, have intensified scrutiny of cost-effectiveness and utilization management mechanisms, prompting manufacturers to accelerate value-based contracting approaches and to prepare more robust outcomes data to support reimbursement discussions. In addition, tariffs have encouraged some organizations to invest in domestic manufacturing capabilities or to explore strategic partnerships to insulate supply continuity.

Although tariffs have increased friction, they have also catalyzed adaptive strategies that emphasize regional resilience, regulatory harmonization efforts, and commercial models centered on demonstrable patient benefit. Stakeholders who prioritize supply chain transparency, flexible production, and collaborative contracting are more likely to navigate the evolving trade landscape successfully.

Critical segmentation-driven insights that connect therapeutic classes, cancer types, molecule categories, administration routes and distribution pathways to commercial and clinical strategy

Segmentation illuminates distinct clinical needs and commercial pathways that demand tailored approaches from developers and providers. Based on therapeutic class, the landscape includes chemotherapy alongside combination therapy, immunotherapy with CTLA-4, PD-1, and PD-L1 inhibitors, and targeted therapy encompassing ALK, EGFR, and ROS1 inhibitors; each class carries unique efficacy profiles, safety considerations, and monitoring requirements that influence formulary and prescribing patterns. Based on cancer type, treatment paradigms differ between Non Small Cell Lung Cancer and Small Cell Lung Cancer, where molecular profiling and therapeutic responsiveness vary significantly and drive different diagnostic and care pathways.

Based on molecule type, monoclonal antibodies and small molecule drugs present divergent manufacturing, storage, and administration challenges that affect distribution channels and payer negotiations. Based on route of administration, oral and parenteral therapies require distinct adherence supports and infrastructure, with oral agents often enabling home-based care while parenteral regimens remain tethered to clinic and hospital infusion resources. Based on end user, treatment delivery spans homecare settings, hospitals, and specialty clinics, each imposing different operational workflows, reimbursement codes, and staffing profiles that must be addressed in go-to-market plans.

Finally, based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each shape access, patient convenience, and cost structures. Integrating these segmentation lenses provides a granular perspective on patient journeys, commercial levers, and value communication that can be operationalized across development, market access, and field engagement activities.

Regional strategic perspectives that link regulatory nuance, diagnostic readiness and care delivery patterns across the Americas, Europe Middle East & Africa and Asia-Pacific to commercialization choices

Regional dynamics materially influence clinical practice, regulatory expectations, and commercial viability across the lung cancer therapeutic space. In the Americas, regulatory agility, payer competitiveness, and advanced diagnostic infrastructure support rapid adoption of immunotherapies and targeted agents, while fragmented payer landscapes require nuanced access strategies and robust health economic evidence. Transitioning from acute hospital-centered care to outpatient and home-based administration is especially evident in large oncology centers and integrated delivery networks across this region, prompting firms to calibrate distribution and support services accordingly.

In Europe, the Middle East & Africa, heterogeneous reimbursement models, variable diagnostic capacity, and distinct regulatory pathways shape adoption timelines. Stakeholders in this region contend with differential access to next-generation sequencing and biologic therapies, driving the need for tiered launch strategies and partnerships with regional diagnostic and clinical networks. Meanwhile, in Asia-Pacific, rapid investment in diagnostic capacity, growth of domestic manufacturing, and strong government interest in expanding cancer care access are creating fertile conditions for both global and local players to pursue innovative collaborations. Across regions, localized pricing pressures and supply chain considerations necessitate adaptive commercial approaches that reflect regional infrastructure, regulatory nuance, and payer priorities.

Ultimately, regional insight should inform prioritization of clinical development, market entry sequencing, and partnership models so that resources align with patient needs and systemic capabilities.

How leading pharmaceutical and biotechnology companies are integrating pipelines, diagnostics, manufacturing resilience and value-based contracting to compete in lung cancer therapeutics

Leading companies are evolving beyond single-product strategies toward integrated platforms that combine pipeline depth, diagnostic partnerships, and commercial support to sustain long-term competitiveness. Innovative firms are prioritizing development of both monoclonal antibodies and small molecule agents to address complementary patient populations, while investing in companion diagnostics to secure biomarker-driven prescribing and to streamline regulatory interactions. Strategic alliances, licensing agreements, and selective acquisitions are frequently used to bolster portfolios, accelerate access to novel mechanisms of action, and expand manufacturing capabilities, particularly for biologics that require specialized production.

Operationally, companies are building capabilities in cold-chain logistics, patient support programs, and digital therapeutics that enhance adherence and real-world outcomes reporting. They are also negotiating outcome-based contracts with payers and health systems, placing emphasis on longitudinal evidence generation and registries to demonstrate value. At the same time, resource allocation increasingly favors therapies with clear biomarker-driven patient selection, improved tolerability, or significant quality-of-life benefits, reflecting payer expectations and clinical demand.

As competition intensifies, corporate differentiation will derive from the ability to integrate clinical science with pragmatic commercialization, manufacturing resilience, and compelling evidence of patient-centered benefit.

Practical and actionable recommendations that align clinical development, supply chain resilience, diagnostics integration and payer-focused evidence generation to strengthen competitive positioning

Industry leaders should adopt a portfolio approach that balances innovation with supply chain resilience and payer-aligned evidence generation. Prioritize investment in companion diagnostics and next-generation sequencing partnerships to ensure actionable biomarker identification, which in turn optimizes patient selection and strengthens value propositions during reimbursement negotiations. Simultaneously, diversify sourcing and consider strategic regional manufacturing or co-manufacturing agreements to reduce exposure to tariff-driven cost volatility and to support reliable clinical trial supply.

Operationally, expand capabilities for outpatient and home-based administration through patient support programs, telehealth integration, and adherence monitoring solutions that reduce healthcare system burden and improve therapeutic continuity. Strengthen commercial arguments by collecting prospective real-world evidence and constructing outcomes-based contracting frameworks that align payment with measurable clinical benefit. Finally, pursue collaborative research with academic centers and health systems to design pragmatic clinical studies that address unmet clinical questions, safety in diverse populations, and comparative effectiveness, thereby enhancing dialogue with regulators and payers about meaningful endpoints.

A transparent and rigorous research methodology integrating primary expert interviews, secondary literature synthesis and data triangulation to validate clinical and operational insights

The research methodology combines structured primary research, comprehensive secondary review, and rigorous synthesis to ensure findings are robust and actionable. Primary research included in-depth interviews with clinical specialists, pharmacovigilance experts, supply-chain leaders, and payers, complemented by advisory-panel discussions to validate interpretation of emergent trends. Secondary research encompassed regulatory filings, peer-reviewed literature, clinical-trial registries, published guidance from health authorities, and company disclosures to cross-check clinical claims, safety profiles, and approval pathways.

Data integration relied on triangulation to reconcile disparate sources and to surface consistent signals about treatment adoption, operational challenges, and strategic behaviors. Where appropriate, sensitivity analyses were performed to test assumptions and to understand the implications of policy changes, including tariff effects on supply and distribution. Limitations of the approach are acknowledged: real-world practice can evolve rapidly, and emerging clinical trial data may alter therapeutic positioning. Therefore, the methodology emphasizes transparency in data sources, stakeholder validation, and continual monitoring to maintain relevance as the landscape evolves.

A concluding synthesis outlining how scientific progress, diagnostic precision and operational adaptations must coalesce to convert therapeutic promise into accessible and sustainable care

In summary, the lung cancer therapeutic landscape is characterized by rapid scientific progress, shifting delivery models, and complex commercial dynamics that require coordinated strategic responses. Advances in immunotherapy and targeted agents are altering treatment algorithms while diagnostic innovation enables more granular patient selection. At the same time, policy shifts and trade dynamics have exposed vulnerabilities in supply chains and pricing that necessitate proactive mitigation measures.

Stakeholders who align biomarker-driven development with pragmatic distribution strategies, invest in domestic or regional manufacturing resilience, and embrace outcomes-based engagement models with payers will be better positioned to deliver sustained patient benefit. Cross-functional collaboration among developers, diagnostics providers, providers, and payers is essential to translate therapeutic potential into accessible, safe, and economically sustainable care. Continued surveillance of clinical trial results, regulatory decisions, and regional access dynamics will be critical to iteratively refine strategy and to ensure that innovations reach the patients who can benefit most.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid adoption of KRAS G12C inhibitors reshaping second-line NSCLC treatment strategies
• 5.2. Integration of liquid biopsy minimal residual disease monitoring to guide adjuvant NSCLC therapy decisions
• 5.3. Expansion of bispecific antibodies targeting PD-L1 and LAG-3 in early-stage lung cancer clinical trials
• 5.4. Emergence of personalized neoantigen vaccines enhancing immunotherapy efficacy in lung tumor management
• 5.5. Acceleration of combination regimens with EGFR inhibitors and VEGF antagonists in EGFR-mutant NSCLC

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Drugs Market, by Therapeutic Class

• 8.1. Chemotherapy
• 8.2. Combination Therapy
• 8.3. Immunotherapy
  • 8.3.1. Ctla-4 Inhibitors
  • 8.3.2. Pd-1 Inhibitors
  • 8.3.3. Pd-L1 Inhibitors
• 8.4. Targeted Therapy
  • 8.4.1. Alk Inhibitors
  • 8.4.2. EgfR Inhibitors
  • 8.4.3. Ros1 Inhibitors

9. Lung Cancer Drugs Market, by Cancer Type

• 9.1. Non Small Cell Lung Cancer
• 9.2. Small Cell Lung Cancer

10. Lung Cancer Drugs Market, by Molecule Type

• 10.1. Monoclonal Antibodies
• 10.2. Small Molecule Drugs

11. Lung Cancer Drugs Market, by Route Of Administration

• 11.1. Oral
• 11.2. Parenteral

12. Lung Cancer Drugs Market, by End User

• 12.1. Homecare Settings
• 12.2. Hospitals
• 12.3. Specialty Clinics

13. Lung Cancer Drugs Market, by Distribution Channel

• 13.1. Hospital Pharmacy
• 13.2. Online Pharmacy
• 13.3. Retail Pharmacy

14. Lung Cancer Drugs Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Lung Cancer Drugs Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Lung Cancer Drugs Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Hoffmann-La Roche Ltd
  • 17.3.2. AstraZeneca PLC
  • 17.3.3. Merck & Co., Inc.
  • 17.3.4. Bristol-Myers Squibb Company
  • 17.3.5. Pfizer Inc.
  • 17.3.6. Novartis International AG
  • 17.3.7. Boehringer Ingelheim International GmbH
  • 17.3.8. Janssen Pharmaceutical Companies of Johnson & Johnson
  • 17.3.9. AbbVie Inc.
  • 17.3.10. Amgen Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. LUNG CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. LUNG CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. LUNG CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL LUNG CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 167. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 168. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 169. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 170. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 171. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 172. AMERICAS LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 185. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 186. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 187. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 188. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 189. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 190. NORTH AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 203. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 204. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 205. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 206. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 207. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 208. LATIN AMERICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 257. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 258. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 259. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 260. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 261. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 262. MIDDLE EAST LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 275. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 276. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 277. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 279. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 280. AFRICA LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 293. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 294. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 295. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 296. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 297. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 298. ASIA-PACIFIC LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 299. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 300. GLOBAL LUNG CANCER DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 305. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 306. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 307. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 308. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 309. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 310. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 311. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 312. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 313. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 314. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 315. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 316. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 317. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 318. ASEAN LUNG CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 319. GCC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 320. GCC LUNG CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 321. GCC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
• TABLE 322. GCC LUNG CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
• TABLE 323. GCC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 324. GCC LUNG CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 325. GCC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 326. GCC LUNG CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 327. GCC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 328. GCC LUNG CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 329. GCC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 330. GCC LUNG CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 331. GCC LUNG CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)

TABL